^
Association details:
| Biomarker: | GNA11 mutation |
|---|---|
| Cancer: | Uveal Melanoma |
| Drug: | Mektovi (binimetinib) (MEK inhibitor) + sotrastaurin (AEB071) (PKC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
Excerpt:
Similarly as AEB071 + CGM097, the AEB071 + MEK162 combination induced significant TGI in all five PDXs associated with combination activity in four models (Figure (Figure11 and Supplementary Figure S4)….Overall, our in vivo findings show that targeting of PKC and p53-MDM2 or PKC and mTORC1 are effective combination strategies for GNAQ/11 mutated UM PDXs, with tumor regressions often observed after PKC and p53-MDM2 inhibition.
DOI:
10.18632/oncotarget.9552
